Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2018 Nov;6(Suppl 1):S60.
doi: 10.21037/atm.2018.10.26.

Dasatinib in breast cancer: Src-ing for response in all the wrong kinases

Laura C Kennedy  1   2 , Vijayakrishna Gadi  1   2
Affiliations
Editorial

Dasatinib in breast cancer: Src-ing for response in all the wrong kinases

Laura C Kennedy et al. Ann Transl Med. 2018 Nov.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Dr. Gadi has the following conflicts of interest: SEngine Precision Medicine (ownership and consulting), Novartis (consulting), Pfizer (consulting), Daichii Sankyo (consulting), Seattle Genetics (consulting), and Genentech (research funding). LC Kennedy has no conflicts of interest to declare.

Comment on

  • Phase II Study of Paclitaxel and Dasatinib in Metastatic Breast Cancer.
    Morris PG, Rota S, Cadoo K, Zamora S, Patil S, D'Andrea G, Gilewski T, Bromberg J, Dang C, Dickler M, Modi S, Seidman AD, Sklarin N, Norton L, Hudis CA, Fornier MN. Morris PG, et al. Clin Breast Cancer. 2018 Oct;18(5):387-394. doi: 10.1016/j.clbc.2018.03.010. Epub 2018 Mar 15. Clin Breast Cancer. 2018. PMID: 29680193 Free PMC article. Clinical Trial.

References

    1. Rucci N, Recchia I, Angelucci A, et al. Inhibition of protein kinase c-Src reduces the incidence of breast cancer metastases and increases survival in mice: implications for therapy. J Pharmacol Exp Ther 2006;318:161-72. 10.1124/jpet.106.102004 - DOI - PubMed
    1. Saad F, Lipton A. SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancer. Cancer Treat Rev 2010;36:177-84. 10.1016/j.ctrv.2009.11.005 - DOI - PubMed
    1. Rose AA, Siegel PM. Emerging therapeutic targets in breast cancer bone metastasis. Future Oncol 2010;6:55-74. 10.2217/fon.09.138 - DOI - PubMed
    1. Morris PG, Rota S, Cadoo K, et al. Phase II Study of Paclitaxel and Dasatinib in Metastatic Breast Cancer. Clin Breast Cancer 2018;18:387-94. 10.1016/j.clbc.2018.03.010 - DOI - PMC - PubMed
    1. Zhang XH, Wang Q, Gerald W, et al. Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell 2009;16:67-78. 10.1016/j.ccr.2009.05.017 - DOI - PMC - PubMed